<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895386</url>
  </required_header>
  <id_info>
    <org_study_id>US HTN-01</org_study_id>
    <nct_id>NCT02895386</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension</brief_title>
  <official_title>A Prospective, Randomized, Adaptive, Double-Blind, Sham-Controlled, Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ROX Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ROX Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the ROX Coupler used to create an arteriovenous
      anastomosis in the iliac region (between the iliac artery and vein) in subjects with
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean 24-hour Ambulatory Blood Pressure Monitor systolic blood pressure</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in mean 24-hour Ambulatory Blood Pressure Monitor systolic blood pressure at six month as compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24-hour Ambulatory Blood Pressure Monitor diastolic blood pressure</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in mean 24-hour Ambulatory Blood Pressure Monitor diastolic blood pressure at six months as compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ROX Coupler implantation and continuing antihypertensive medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group B</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure and continuing current antihypertensive medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ROX Coupler</intervention_name>
    <description>ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <arm_group_label>Control Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hypertension must be made on basis of current findings, medical history,
             and physical examination.

        Exclusion Criteria:

          -  Any serious medical condition that may adversely affect the patient's safety, limit
             the subject's ability to participate in the study, comply with follow-up requirements
             or impact the scientific integrity of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Krishna Rocha-Singh, MD</last_name>
    <phone>217-527-3700</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Plessa, MPH</last_name>
    <phone>217-492-9103</phone>
    <email>aplessa@prairieresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Deramus, RN, CCRN</last_name>
      <phone>205-949-5275</phone>
      <email>SDeramus@cardiologypc.com</email>
    </contact>
    <contact_backup>
      <last_name>Kris Armstrong, RN</last_name>
      <phone>205-780-4330</phone>
      <phone_ext>5337</phone_ext>
      <email>karmstrong@cardiologypc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Farrell O Mendelsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Vascular Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Plessa, MPH</last_name>
      <phone>217-492-9103</phone>
      <email>aplessa@prairieresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Raegan Hamrick</last_name>
      <phone>217-492-9120</phone>
      <email>RHamrick@prairieresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krishna Rocha-Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.roxmedical.com</url>
  </link>
  <reference>
    <citation>Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, van der Giet M, Hoyer J, Furniss SS, Foran JP, Witkowski A, Januszewicz A, Schoors D, Tsioufis K, Rensing BJ, Scott B, Ng GA, Ott C, Schmieder RE; ROX CONTROL HTN Investigators.. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015 Apr 25;385(9978):1634-41. doi: 10.1016/S0140-6736(14)62053-5. Epub 2015 Jan 23. Erratum in: Lancet. 2016 Feb 13;387(10019):648. Lancet. 2015 Apr 25;385(9978):1622.</citation>
    <PMID>25620016</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>September 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
